Navigation Links
P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth
Date:10/29/2008

of 1995. Such statements are based on financial data, market assumptions and business plans available only as of the time the statements are made, which may become out of date or incomplete. We assume no obligation to update any forward-looking statement as a result of new information, future events or other factors. Forward-looking statements are inherently uncertain, and investors must recognize that events could differ significantly from our expectations. In addition to the risks and uncertainties noted in this release, there are certain factors that could cause actual results to differ materially from those anticipated by some of the statements made. These include: (1) the ability to achieve business plans, including with respect to lower income consumers and growing existing sales and volume profitably despite high levels of competitive activity, especially with respect to the product categories and geographical markets (including developing markets) in which the Company has chosen to focus; (2) the ability to successfully execute, manage and integrate key acquisitions and mergers and to achieve the cost and growth synergies in accordance with the stated goals of these transactions; (3) the ability to manage and maintain key customer relationships; (4) the ability to maintain key manufacturing and supply sources (including sole supplier and plant manufacturing sources); (5) the ability to successfully manage regulatory, tax and legal matters (including product liability, patent, intellectual property, and competition law matters), and to resolve pending matters within current estimates; (6) the ability to successfully implement, achieve and sustain cost improvement plans in manufacturing and overhead areas, including the Company's outsourcing projects; (7) the ability to successfully manage currency (including currency issues in volatile countries), debt, interest rate and commodity cost exposures and significant credit or liquidity issues; (8) the ability to m
'/>"/>
SOURCE The Procter & Gamble Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Cardinal Health Reports First Quarter Results
2. uKarma Reports Progress With International Distribution Agreement for Its Xflowsion DVD Series
3. STAAR Surgical Reports 33% Third Quarter Revenue Growth
4. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
5. Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008
6. LCA-Vision Reports Third Quarter 2008 Financial Results
7. Universal Health Services, Inc. Reports 2008 Third Quarter Results
8. PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results
9. Sharps Compliance Corp. Reports Net Income More Than Doubles on 26% Increase in Revenue in the First Quarter of Fiscal 2009
10. WellPoint Reports Third Quarter 2008 Results
11. Forest Laboratories, Inc. Reports Fiscal Second Quarter 2009 Earnings per Share of $0.80
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... Pentec Health, Inc. number fourteen on the Best ... 2014. The awards program, created in 2000, is one ... the country. The program is a public/private partnership between ... Economic Development, the Pennsylvania State Council of the Society ... Journal. , Charlie Wilson, Vice President of ...
(Date:12/26/2014)... Parker & Sons, Inc. a reliable ... cooling and plumbing contractor services throughout Arizona announces ... 2014 with regard to air-conditioning systems. Residential and ... for its incredibly hot summers. Working with an ... details of a wide variety of systems made ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 This ... state of the global Sterilizers industry with a focus ... on the market status of the Sterilizers manufacturers and ... companies and individuals interested in the industry. This report ... definition, applications and manufacturing technology. In this part, the ...
(Date:12/25/2014)... 26, 2014 The report “Nintedanib ... 2023” focuses on the current treatment landscape, unmet ... colorectal cancer market. Stivarga is a drug which ... rectal cancer. Boehringer Ingelheim is developing nintedanib (BIBF-1120), ... of refractory CRC in the US, Europe, and ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Product liability ... ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move ... to an Order issued in the U.S. District Court, ... will convene an open conference on January 7, 2015, ... States Courthouse in West Palm Beach, Florida. The Conference ...
Breaking Medicine News(10 mins):Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3
... & Lomb, the global eye health company, has entered ... for the development of certain intraocular lens (IOL) materials. ... has obtained the rights to Santen,s hydrophobic acrylic polymers, ... worldwide. Santen reserves the right for the use of ...
... March 3 Marinus Pharmaceuticals, Inc. today announced that ... clinical trial investigating the safety and efficacy of ganaxolone ... a type of epilepsy. In this trial, ganaxolone ... Efficacy was seen in the first week of ...
... supplies has unveiled their annual 2009 list of what to do if ... ... Nationwide Medical/Surgical , a distributor of the flu vaccine and flu ... if exposed to the flu virus., , ,The flu is a highly ...
... Study finds it alters levels of hormones, could raise risk ... 2 -- Working the night shift might lead to hormonal ... heart disease, researchers say. , "In the long run, the ... the regulation of body weight -- leptin, insulin, cortisol -- ...
... KIRKLAND, Wash., Feb 26 ProteoTech Inc. announced ... from The Michael J. Fox Foundation for Parkinson,s ... (Philadelphia, PA), ProteoTech scientists will utilize ProteoTech,s small ... agents that will allow doctors to use PET ...
... 2 Speaker Nancy Pelosi released the following ... Sebelius as Secretary of the Department of Health and ... leader who has worked to expand health care access ... drugs. "Governor Sebelius, deep understanding of health care issues ...
Cached Medicine News:Health News:Bausch & Lomb, Santen Strike Licensing Agreement for IOL Development 2Health News:Marinus Pharmaceuticals, Inc. Announces Positive Results of its Phase 2 Clinical Trial of Ganaxolone as Adjunctive Therapy in Adults With Partial Onset Seizures 2Health News:Marinus Pharmaceuticals, Inc. Announces Positive Results of its Phase 2 Clinical Trial of Ganaxolone as Adjunctive Therapy in Adults With Partial Onset Seizures 3Health News:Marinus Pharmaceuticals, Inc. Announces Positive Results of its Phase 2 Clinical Trial of Ganaxolone as Adjunctive Therapy in Adults With Partial Onset Seizures 4Health News:Nationwide Medical/Surgical Reveals Their Help Sheet For Those Infected with Influenza Virus 2Health News:Night Shift Work Hard on the Heart 2Health News:Night Shift Work Hard on the Heart 3Health News:ProteoTech Receives Funding From The Michael J. Fox Foundation for Parkinson's Disease Research to Develop Tools for Imaging Alpha-Synuclein Aggregation in Living Parkinson's Brain 2
(Date:12/24/2014)... Dec. 23, 2014   Assurex Health, a ... to healthcare providers for behavioral health and chronic ... $30 million in equity financing from new and ... , President and Chief Executive Officer. ... development of Assurex Health,s GeneSight ® ...
(Date:12/24/2014)... 23, 2014 Tianyin Pharmaceutical Co., Inc. ... in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), ... announced that the Company achieved the Public Notice ... (GMP) certificate of TPI,s Qionglai Facility (QLF) from ... public notice period is a significant procedure of ...
(Date:12/24/2014)... Dec. 23, 2014  Medical Science Liaisons play a ... link between the medical device industry and key stakeholders, ... the coming years as the device industry relies on ... to research by benchmarking firm, Best Practices, LLC, one ... important edge is by harnessing new technology to enable ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Role of Medical Science Liaisons Evolving in Medical Device Sector 2
... Trial Raise Questions for,Patients, OAK BROOK, Ill., ... Trial, published in the September 18 issue of ... the technology,s,ability to diagnose intermediate- to large-sized polyps ... not as effective in diagnosing small polyps. CT,colonography ...
... Study Results Published in the September 18th New England ... die from colorectal cancer. Many,of these deaths could be ... 50 and older who should be screened for the ... cost, inconvenience, and safety,concerns associated with current screening exams., ...
Cached Medicine Technology:ASGE Encourages Patients to Speak to Their Doctor About Colorectal Cancer Screening Options 2ASGE Encourages Patients to Speak to Their Doctor About Colorectal Cancer Screening Options 3ASGE Encourages Patients to Speak to Their Doctor About Colorectal Cancer Screening Options 4ASGE Encourages Patients to Speak to Their Doctor About Colorectal Cancer Screening Options 5MultiVu Video Feed: Major Trial Demonstrates Comparable Accuracy of Virtual Colonoscopy and Standard Colonoscopy 2
Integrated electronics, three-chip CCD camera with PAL and NTSC output at 750 lines, RGB-video. 44mm x 49mm x 75mm, 180 grams....
Large image and wide-angle design....
High intensity halogen lamp with built-in, switchable spare. Optical light concentrator to optimize existing light energy....
PDA application listing specific ICD-9 coding listed in new Medicare National Coverage Determinations....
Medicine Products: